8-K: SS Innovations Reports Global Expansion and Robotic Surgery Milestones

SS Innovations International, Inc. announced significant progress in global expansion, pediatric robotic surgery, and telesurgery, alongside growing installations and utilization of its SSi Mantra system.

Summary

• SS Innovations International, Inc. (SSi) provided an update on its progress and milestones, focusing on global expansion, pediatric robotic surgery, and telesurgery.
• The company reported the launch of robotic cardiac surgery in Colombia and the installation of the first SSi Mantra system in Sri Lanka, which has already performed over 25 robotic surgeries.
• The SSi Mantra's global installed base now spans 12 countries, with a significant presence in India.
• SSi anticipates U.S. FDA review completion for its 510(k) premarket notification by Q1 2027 and expects EU CE marking by the end of 2026.
• A successful robotic pyeloplasty was performed on a 45-day-old infant using the SSi Mantra, demonstrating its capability in pediatric surgery, with 258 cumulative pediatric robotic surgeries as of August 31, 2026.
• The company achieved the longest-distance telesurgery record (over 13,600 miles) and expanded its telesurgery ecosystem in India and launched it in the Philippines.
• As of August 31, 2026, 188 robotic telesurgeries have been completed.
• On August 15, 2026, five SSi Mantra systems completed 50 robotic general surgery procedures in a single day.
• As of September 8, 2026, the cumulative installed base reached 238 systems (up 42% from end of 2025), and total procedures reached 14,103 (up 79% from end of 2025).
• Approximately 1,500 physicians have been trained on the SSi Mantra, used for over 170 different surgical procedures.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive update, highlighting significant global expansion, technological advancements in pediatric and telesurgery, and strong growth in installations and procedures, indicating robust operational progress.

Positives

• Successful launch of robotic cardiac surgery program in Colombia.
• Installation of the first SSi Mantra in Sri Lanka, leading to over 25 robotic surgeries within three weeks.
• Global installed base expanded to 12 countries.
• Anticipated U.S. FDA review completion by Q1 2027 and EU CE marking by end of 2026.
• Demonstrated capability in intricate pediatric robotic surgery, with 258 cumulative procedures.
• Set a new longest-distance telesurgery record (over 13,600 miles).
• Expanded telesurgery operations in India and launched in the Philippines.
• Achieved 50 robotic general surgery procedures in a single day using multiple SSi Mantra systems.
• Significant growth in installed base (42% year-over-year) and total procedures (79% year-over-year) as of September 8, 2026.
• Broad surgeon adoption with 1,500 physicians trained on the system for over 170 procedure types.

Negatives

• U.S. FDA review is still pending, with an expected completion by the end of the first quarter of 2027.
• European Union CE marking certification is still pending, with an expected completion by the end of 2026.

Risks

• The forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied.
• Regulatory approval processes in the U.S. and EU are ongoing and subject to timelines that may shift.

Future Outlook

SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027. The company also believes that European Union CE marking certification can be obtained by the end of 2026.

Management Comments

• "Our advanced, cost-effective SSi Mantra surgical robotic system is benefitting lives globally, one patient at a time, from a 45-day old baby needing kidney surgery in India to a cardiac patient in Sri Lanka."
• "Our progress in democratizing access to state-of-the-art surgical robotic care continues to be reflected in growing SSi Mantra installations, procedures and utilization."

Industry Context

StockSavvy.ai notes that SS Innovations is operating in the rapidly growing surgical robotics market, which is increasingly focused on making advanced technologies more accessible and affordable globally. The company's progress in emerging markets and its focus on telesurgery align with broader industry trends towards remote healthcare delivery and expanding surgical capabilities in underserved regions.

Comparison to Industry Standards

• The company's achievement of 14,103 cumulative procedures and 238 installed systems positions it as a growing player in the global surgical robotics market, though still smaller than established giants like Intuitive Surgical.
• The record-breaking telesurgery distance of over 13,600 miles highlights SS Innovations' commitment to pushing the boundaries of remote surgical capabilities, an area of increasing interest across the industry.
• The focus on pediatric robotic surgery with specialized 5mm instrumentation addresses a niche but critical segment of the market, where precision is paramount and often requires tailored solutions.

Stakeholder Impact

• Shareholders: Positive impact expected from continued growth in installations, procedures, and global expansion, potentially leading to increased market share and revenue.
• Patients: Increased access to advanced robotic surgery, particularly in pediatric and complex cases, due to global expansion and affordability focus.
• Healthcare Providers: Growing adoption of SSi Mantra system, offering advanced surgical capabilities and potentially improving patient outcomes.
• Employees: Continued growth may lead to expansion and new opportunities within the company.

Next Steps

• Await completion of U.S. FDA review of the 510(k) premarket notification by the end of Q1 2027.
• Obtain European Union CE marking certification by the end of 2026.
• Continue to expand global installations and utilization of the SSi Mantra system.
• Further develop and deploy telesurgery capabilities.

Key Dates

Recommendation

The filing presents strong operational progress and growth metrics, particularly in installations and procedures, and highlights significant advancements in telesurgery and pediatric applications. However, the reliance on future regulatory approvals (FDA and CE marking) introduces a degree of uncertainty. While positive, the current stage of development and pending approvals warrant a 'hold' recommendation, pending further clarity on regulatory timelines and market penetration.

Keywords

surgical robotic system, robotic surgery, telesurgery, pediatric surgery, global expansion, SSi Mantra, medical technology, healthcare innovation